Management of ACS for the ALS Provider

References
  1. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985; 6:199.
  2. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353:89.
  3. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012; 366:321.
  4. Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. JAMA 2010; 303:2148.
  5. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.
  6. McGinn AP, Rosamond WD, Goff DC Jr, et al. Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987-2000. Am Heart J 2005; 150:392.
  7. Measure summary: acute myocardial infarction: median time to transfer to another facility for acute coronary intervention. http://www.qualitymeasures.ahrq.gov/content.aspx?id=13121 (Accessed on July 07, 2011).
  8. Hajat C, Harrison O. The Abu Dhabi Cardiovascular Program: the continuation of Framingham. Prog Cardiovasc Dis 2010; 53:28.
  9. Reddy KS, Satija A. The Framingham Heart Study: impact on the prevention and control of cardiovascular diseases in India. Prog Cardiovasc Dis 2010; 53:21.
  10. Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010; 39:504.
  11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.
  12. Colombo A, Stankovic G, Moses JW. Selection of coronary stents. J Am Coll Cardiol 2002; 40:1021.
  13. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.
  14. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.
  15. Anderson HV, Shaw RE, Brindis RG, et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 2002; 39:1096.
  16. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92:824.
  17. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.
  18. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.
  19. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270:1211.
  20. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113:791.
  21. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743.
  22. Wilson PW. Challenges to improve coronary heart disease risk assessment. JAMA 2009; 302:2369.
  23. Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100:1481.
  24. Nuttall SL, Toescu V, Kendall MJ. beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. BMJ 2000; 320:581.
  25. Bryan E. Bledsoe, Frederick H. Martini, Edwin F. Bartholomew. Anatomy and Physiology for Emergnecy Care. Published by: Brady / Prentice Hall William C. Ober, Claire W. Garrison ©2007
  26. 12-Lead ECG in the Acute Coronary Syndromes Student Manual Volumes 1-3 by: ACS Consultants, Inc. ©2000 Published by: Medtronic Physio-Control Corp.
  27. Bryan E. Bledsoe, Robert S. Porter, Richard A. Cherry. Essentials of Paramedic Care, 2nd Edition ©2006 Published by Brady / Prentice Hall
  28. Massachusetts Statewide Treatment Protocols. Tenth Edition, Official Version 10.01 Effective 3/1/2012. MA DPH OEMS www.ma.gov/dph/oems
  29. American Heart Association. ACLS Provider Manual (2020 Guidelines). October 2020. Dallas, TexasMalinow MR, Bostom AG, Krauss RM. Homocysteine, diet and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999; 99: 178
  30.  Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999; 99: 178
  31. Maurer PM and Bartkowski RR, “Drug Interactions of Clinical Significance With Opiad Analgesics,” Drug Saf, 1993, 8(1):30-48. [PubMed 8471186]
  32. Centers for Disease Control and Prevention. “Heart Disease Facts.” Centers for Disease Control and Prevention, 15 May 2023, www.cdc.gov/heartdisease/facts.htm.